Key Points

  • Amazon is now trading near its lowest EV/EBIT valuation level in more than a decade
  • Compressed profitability and a sharp rise in interest rates pushed the multiple downward
  • Despite strong momentum in AWS and AI, investors remain cautious about future margins
hero

Amazon is confronting one of the most pivotal valuation phases in its history. For years the company symbolized unstoppable technological expansion — an integrated empire of e-commerce, cloud infrastructure, logistics, AI and consumer devices. Today, however, Amazon is priced more like a company under macro stress than a global leader. Its EV/EBIT multiple has fallen toward 27, a level last seen during periods of pronounced market tension.

In the previous decade Amazon consistently enjoyed premium valuations, often three to four times higher than current levels. During 2021–2022 the multiple surged to 120–160, reflecting near-unquestioned belief in endless growth. The contraction in valuation marks a profound shift in investor psychology, as the market transitions from “growth at any cost” to a stricter focus on operating profitability and cash generation.

Much of the decline stems from pressure on core profitability. Heavy investment in fulfillment infrastructure, automation, logistics fleets, AWS expansion and AI-related capabilities weighed on EBIT. These investments build long-term strategic leverage, but they suppress short-term margins — and when interest rates rise sharply, the market loses patience with long-duration promises.

This psychological shift is evident across the technology sector. Investors who once treated mega-caps as exceptions now evaluate them like any other business: how much profit they produce, how stable it is and how fast it grows.

At the same time, Amazon’s operational engines are showing meaningful recovery. AWS is regaining momentum after a period of deceleration, supported by renewed enterprise spending and accelerating demand for AI infrastructure. With workloads from AI-native companies like Anthropic and thousands of mid-size firms, AWS is positioned to reclaim its role as Amazon’s most profitable division.

The retail segment is also undergoing a structural reset. After an unprecedented surge in pandemic-era expenses, Amazon has restored discipline to its supply chain, leveraging automation, faster fulfillment and advanced pricing systems. These efficiencies are beginning to strengthen margins and could continue contributing meaningfully in the coming quarters.

Artificial intelligence represents Amazon’s next long-term strategic vector. The company is allocating billions to generative-AI models, robotics and cloud-native AI platforms. The combination of AWS’s scale with vertically integrated AI capabilities could generate revenue streams that are not yet reflected in today’s valuation — much like early cloud investments that seemed speculative a decade ago and eventually became a dominant profit engine.

Still, market skepticism persists. Competitive intensity in cloud services is rising as Microsoft Azure and Google Cloud accelerate their product cycles. AI-related capex remains heavy and monetization timelines are uncertain. Meanwhile, signs of consumer softening in the U.S. create a headwind for Amazon’s retail operations.

These conflicting dynamics create a valuation puzzle. On one hand, Amazon is trading at a historically depressed multiple; on the other, its business fundamentals are strengthening in real time. If profitability continues to recover, the market will eventually re-rate the stock upward. But if elevated spending fails to translate into sustained margin expansion, the current discount could prove justified.

The gap between operational reality and investor sentiment has rarely been wider. The core question is whether this dislocation represents a classic contrarian entry point — or a credible warning that Amazon’s next growth cycle may be more challenging than the last.


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Nvidia Shares Slide on Reports of Google Advancing AI Chip Competition
    • Ronny Mor
    • 5 Min Read
    • ago 10 hours

    SKN | Nvidia Shares Slide on Reports of Google Advancing AI Chip Competition SKN | Nvidia Shares Slide on Reports of Google Advancing AI Chip Competition

    Nvidia shares declined in early trading as reports emerged that Google is making significant advances in designing AI-specific processors, positioning

    • ago 10 hours
    • 5 Min Read

    Nvidia shares declined in early trading as reports emerged that Google is making significant advances in designing AI-specific processors, positioning

    SKN | Why Alphabet (GOOGL) Stock Is Trading Up Today
    • Lior mor
    • 13 Min Read
    • ago 20 hours

    SKN | Why Alphabet (GOOGL) Stock Is Trading Up Today SKN | Why Alphabet (GOOGL) Stock Is Trading Up Today

    Factors Driving the Increase in Alphabet (GOOGL) Stock Today Today, Alphabet Inc. (GOOGL) stocks are witnessing a noteworthy surge in

    • ago 20 hours
    • 13 Min Read

    Factors Driving the Increase in Alphabet (GOOGL) Stock Today Today, Alphabet Inc. (GOOGL) stocks are witnessing a noteworthy surge in

    SKN | Novo Nordisk’s Alzheimer’s Bet Backfires as Trial Fails, Sending Shares Sharply Lower
    • sagi habasov
    • 7 Min Read
    • ago 1 day

    SKN | Novo Nordisk’s Alzheimer’s Bet Backfires as Trial Fails, Sending Shares Sharply Lower SKN | Novo Nordisk’s Alzheimer’s Bet Backfires as Trial Fails, Sending Shares Sharply Lower

      Novo Nordisk reported a major clinical setback after two large phase-3 studies testing oral semaglutide in early Alzheimer’s failed

    • ago 1 day
    • 7 Min Read

      Novo Nordisk reported a major clinical setback after two large phase-3 studies testing oral semaglutide in early Alzheimer’s failed

    SKN | Bessent Signals Major Health-Care Announcement This Week — What Investors Should Watch
    • Ronny Mor
    • 6 Min Read
    • ago 1 day

    SKN | Bessent Signals Major Health-Care Announcement This Week — What Investors Should Watch SKN | Bessent Signals Major Health-Care Announcement This Week — What Investors Should Watch

    Bessent, a key player in the health-care and biotech sector, has indicated that a major announcement regarding its health-care operations

    • ago 1 day
    • 6 Min Read

    Bessent, a key player in the health-care and biotech sector, has indicated that a major announcement regarding its health-care operations